KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Raw Materials: 2015-2017

Historic Raw Materials for Travere Therapeutics (TVTX) over the last 3 years, with Dec 2017 value amounting to $3.4 million.

  • Travere Therapeutics' Raw Materials rose 17.85% to $3.7 million in Q1 2018 from the same period last year, while for Mar 2018 it was $3.7 million, marking a year-over-year increase of 17.85%. This contributed to the annual value of $3.4 million for FY2017, which is 157.11% up from last year.
  • Per Travere Therapeutics' latest filing, its Raw Materials stood at $3.4 million for FY2017, which was up 157.11% from $1.3 million recorded in FY2016.
  • Travere Therapeutics' 5-year Raw Materials high stood at $3.4 million for FY2017, and its period low was $289,000 during FY2015.
  • Moreover, its 3-year median value for Raw Materials was $1.3 million (2016), whereas its average is $1.7 million.
  • Data for Travere Therapeutics' Raw Materials shows a peak YoY soared of 362.28% (in 2016) over the last 5 years.
  • Over the past 3 years, Travere Therapeutics' Raw Materials (Yearly) stood at $289,000 in 2015, then surged by 362.28% to $1.3 million in 2016, then skyrocketed by 157.11% to $3.4 million in 2017.